Rani Therapeutics Holdings Inc
For the period ended May 29, 2024. Filed Apr 17, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 29, 2024 · Filed Apr 17, 2024
Contents
Cover page
Show cover page
DEF 14A 1 ny20018840x1_def14a.htm DEF 14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
| Filed by the Registrant | | | ☒ | | |
|---|---|---|---|---|---|
| Filed by a Party other than the Registrant | | | ☐ | | |
Check the appropriate box:
| ☐ | | | Preliminary Proxy Statement |
|---|---|---|---|
| ☐ | | | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | | | Definitive Proxy Statement |
| ☐ | | | Definitive Additional Materials |
| ☐ | | | Soliciting Material Pursuant to § 240.14a-12 |
| Rani Therapeutics Holdings, Inc. | |
|---|---|
| (Name of Registrant as Specified In Its Charter) | |
| | |
| | |
| (Name of Person(s) Filing Proxy Statement if other than the Registrant) | |
Payment of Filing Fee (Check all boxes that apply):
| ☒ | | | No fee required. |
|---|---|---|---|
| ☐ | | | Fee paid previously with preliminary materials |
| ☐ | | | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
RANI THERAPEUTICS HOLDINGS, INC.
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on May 29, 2024
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders of RANI THERAPEUTICS HOLDINGS, INC., a Delaware corporation (the “Company”). The meeting will be held on Wednesday, May 29, 2024 at 8:00 a.m. Pacific Time. To facilitate stockholder participation in the Annual Meeting, the Annual Meeting will be held through a live webcast atwww.virtualshareholdermeeting.com/RANI2024. You will not be able to attend the meeting in person. The meeting will be held for the following purposes:
| 1. | To elect the Board’s eight nominees for director, to serve until the next annual meeting and their successors are duly elected and qualified. |
| 2. | To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024. |
| 3. | To conduct any other business properly brought before the meeting. |
These items of business are more fully described in the Proxy Statement accompanying this Notice.
This year's Annual Meeting will be held virtually through a live webcast. You will be able to attend the Annual Meeting and vote during the live webcast by visitingwww.virtualshareholdermeeting.com/RANI2024 and entering the 16-digit Control Number included in your Notice of Internet Availability or in the instructions that you received via email. Please refer to the additional logistical details and recommendations in the accompanying proxy statement. You may log-in beginning at 7:45 a.m. Pacific Time, on May 29, 2024.
The record date for the Annual Meeting is April 2, 2024. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.
By Order of the Board of Directors
| | | |
| Talat Imran | | |
|---|---|---|
| Chief Executive Officer | | |
San Jose, California
April 17, 2024
You are cordially invited to attend the meeting online. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy mailed to you, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting. Even if you have voted by proxy, you may still vote online if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.
RANI THERAPEUTICS HOLDINGS, INC.
PROXY STATEMENT
FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS
To Be Held on May 29, 2024
MEETING AGENDA
| Proposals | | | Page | | | Voting Standard | | | Board Recommendation |
|---|---|---|---|---|---|---|---|---|---|
| Election of Directors | | | 7 | | | Plurality of voting power of shares present virtually or represented by proxy and entitled to vote on the matter | | | For each director nominee |
| · · · · · | |||||||||
| Ratification of the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 | | | 17 | | | Majority of the voting power of shares present virtually or represented by proxy and entitled to vote on the matter | | | For |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.